Market Cap: $653.53B
JJ
Johnson & Johnson
JNJ
NYSE (New York Stock Exchange)USD
Market Cap: $653.53B
Johnson & Johnson (JNJ) has been making significant strides in refocusing its business strategy towards oncology, highlighted by groundbreaking product innovations and strategic acquisitions aimed at…
Johnson & Johnson (Ticker: JNJ) positions itself as a front-runner in the oncology landscape with significant strides regarding its cancer treatment innovation. The European Medicines Agency’s committ…
Johnson & Johnson (Ticker: JNJ) presents new encouraging data on IMAAVY® (nipocalimab-aahu), showcasing its potential in treating generalized myasthenia gravis (gMG) at the European Academy of Neurolo…
Johnson & Johnson (Ticker: JNJ) is undergoing a notable transformation in its strategic priorities as it shifts focus from the obesity drug market to cancer treatments. This decision underscores the c…
Johnson & Johnson (Ticker: JNJ) makes notable strides in oncology with its innovative bispecific antibody TALVEY, which presents promising results in the treatment of relapsed/refractory multiple myel…
Johnson & Johnson (Ticker: JNJ) announces the U.S. launch of its TECNIS PureSee intraocular lens, a groundbreaking development in vision correction for cataract patients. Designed specifically for tho…
Johnson & Johnson (Ticker: JNJ) advances its position in the healthcare sector with promising results from its drug IMAAVY, an innovative treatment for warm autoimmune hemolytic anemia (wAIHA). The Ph…
Johnson & Johnson (Ticker: JNJ) makes strides in the healthcare industry with promising advances in its drug development pipeline, particularly with nipocalimab. Recent data from clinical trials showc…
Johnson & Johnson (Ticker: JNJ) announces a significant milestone with the U.S. Food and Drug Administration's (FDA) approval of a supplemental Biologics License Application for its medication TREMFYA…
Johnson & Johnson (Ticker: JNJ) is advancing its portfolio in cardiovascular treatment through the recent launch of the Shockwave C2 Aero coronary intravascular lithotripsy catheter. This innovative d…
Johnson & Johnson (Ticker: JNJ) has recently announced significant advancements in the treatment of inflammatory bowel diseases (IBD), showcasing its commitment to addressing unmet medical needs in th…
Johnson & Johnson (NYSE: JNJ) has made a significant move in the MedTech sector with its recent acquisition of Atraverse Medical, a company known for its transseptal access solutions designed for mini…
Johnson & Johnson (JNJ) demonstrates promising advancements in the treatment of generalized myasthenia gravis (gMG) with the results from the Phase 3 Vivacity-MG3 study. The study reports long-term ef…
Johnson & Johnson (NYSE: JNJ) reports strong first-quarter earnings that significantly exceed market expectations. The healthcare giant announces a revenue of $24.75 billion, showing an increase compa…
Innovative Partnership to Combat Advanced Prostate Cancer Johnson & Johnson enters a significant clinical supply agreement with GI Innovation, focusing on a combination therapy aimed at treating metas…
Johnson & Johnson Adapts to New Psoriasis Treatment Landscape Following FDA Approval In a notable advancement for dermatological treatments, the U.S. Food and Drug Administration (FDA) has recently ap…
Innovative Oral Solution for Psoriasis: Johnson & Johnson's Icotyde Approved Johnson & Johnson (J&J) celebrates the FDA approval of Icotyde, a groundbreaking oral medication designed to treat moderate…
### Johnson & Johnson Launches Innovative Oral Treatment for Psoriasis Johnson & Johnson (J&J) has revolutionized the treatment landscape for moderate to severe plaque psoriasis with the recent FDA ap…
Johnson & Johnson Introduces Innovative Oral Psoriasis Treatment Johnson & Johnson (J&J) recently receives FDA approval for Icotyde, a once-daily oral medication designed to treat moderate to severe p…
Johnson & Johnson Advances in Bladder Cancer Treatment with Innovative Drug Delivery System Johnson & Johnson's recent advancements in bladder cancer treatment highlight a significant step forward in…
Johnson & Johnson Advances Bladder Cancer Treatment with Promising Study Results Johnson & Johnson (NYSE: JNJ) makes significant strides in the quest for innovative cancer therapies with the recent an…
FDA Expands Approval of Wellcovorin: A Breakthrough for Cancer Treatment On Tuesday, the U.S. Food and Drug Administration (FDA) announced the expanded approval of Wellcovorin (leucovorin calcium) tab…
FDA Approves Expanded Use of Wellcovorin: A Landmark Development for Oncology Treatment The U.S. Food and Drug Administration (FDA) recently grants expanded approval for Wellcovorin (leucovorin calciu…
Resilience and Innovation: Johnson & Johnson's Role in the Health Care Sector The health care sector is renowned for its historical stability and consistent demand, attributes that make it an appealin…
Kenvue Partners with PGA TOUR to Tackle Seasonal Allergies Kenvue, the consumer health division spun off from Johnson & Johnson, takes a significant step by becoming the official "allergy relief spons…
Nipocalimab Advances in SLE Treatment: A Promising Development by Johnson & Johnson Johnson & Johnson (J&J) has recently obtained Fast Track designation from the U.S. Food and Drug Administration (FDA…
Johnson & Johnson Advances Lupus Treatment with FDA Fast Track Designation for Nipocalimab Johnson & Johnson (NYSE: JNJ) solidifies its commitment to addressing chronic autoantibody-driven diseases wi…
### Johnson & Johnson Advances Lupus Treatment with FDA Fast Track Designation Johnson & Johnson (NYSE: JNJ) achieves a significant milestone in the field of autoimmune diseases with the U.S. Food and…
Johnson & Johnson Advances Prostate Cancer Treatment with Promising Clinical Trial Results Johnson & Johnson (J&J) announces encouraging findings from a Phase 1b clinical trial of pasritamig (JNJ-7827…
Johnson & Johnson Advances Treatment for Rare Blood Disorder with IMAAVY® Submission Johnson & Johnson announces the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food…
Johnson & Johnson Advances Innovative Treatment for Rare Autoimmune Condition Johnson & Johnson (J&J) aims to revolutionize the treatment landscape for warm autoimmune hemolytic anemia (wAIHA) with it…
Johnson & Johnson Advances Treatment Options for Autoimmune Disorder with IMAAVY® Submission Johnson & Johnson (J&J) takes a significant step in addressing a critical healthcare gap by submitting a su…
DePuy Separation Accelerates Operational Readiness Johnson & Johnson is advancing plans to separate its DePuy Synthes orthopedics unit and is preparing the business to be an independent, marketable fr…
J&J ramps U.S. advanced‑therapy manufacturing Next‑generation cell and gene plant in Montgomery County Johnson & Johnson is investing more than $1 billion to build a next‑generation cell and gene ther…
Draft offers Janssen and Halozyme names for regulatory-focused summary An assistant in a recent exchange offers to complete a draft by inserting likely company names — Janssen Biotech, the Johnson & J…
Regulatory switch simplifies infusion rhythm for J&J’s Rybrevant Faspro The U.S. Food and Drug Administration approves a simplified monthly dosing schedule for Johnson & Johnson’s Rybrevant Faspro (am…
FDA approves monthly schedule for J&J's Rybrevant Faspro Simplified monthly dosing designed to ease treatment logistics The U.S. Food and Drug Administration is approving a simplified monthly dosing s…
TruDi scrutiny spotlights J&J's surgical AI risks A Reuters investigation finds that artificial intelligence is spreading rapidly through modern healthcare but unevenly, with safety records and regula…
J&J Faces Scrutiny Over AI-Assisted Surgical Tool Acclarent, a Johnson & Johnson subsidiary, is facing renewed scrutiny after a Reuters investigation finds widespread reports of technical failures and…
Johnson & Johnson refocuses on long-term strategy as legal cloud lifts Johnson & Johnson is shifting attention from a shrinking legal overhang toward multi‑year strategic investments as artificial int…
Talc overhang recedes at Johnson & Johnson, prompting strategic reset Johnson & Johnson is moving past a long‑running talc litigation overhang, a development that is freeing management to concentrate…
Healthcare Stability Spotlight: Johnson & Johnson weathers market rotation as investors rethink tech priorities Johnson & Johnson is drawing renewed attention as markets shift focus from high-growth t…
Healthcare refuge: Johnson & Johnson’s appeal as markets rotate away from tech Johnson & Johnson is getting renewed attention as investors and commentators highlight the stabilising role of large heal…
Market volatility pushes attention to defensive health-care names CNBC commentator Jim Cramer is framing recent market turbulence as a catalyst for investors to re-evaluate sector exposures, spotlight…
Johnson & Johnson Prepares for Earnings Amid Market Volatility In a climate of heightened economic uncertainty, Johnson & Johnson (JNJ) stands poised to release its earnings report, a significant even…
Johnson & Johnson Prepares for Earnings Amidst Market Volatility In the backdrop of recent market instability, Johnson & Johnson (JNJ) gears up to report its earnings, showcasing resilience in a chall…
Johnson & Johnson's Focus on Long-Term Growth in Immunology and MedTech As the earnings season heats up, Johnson & Johnson prepares to release its fourth-quarter results on Wednesday morning, with ana…
Johnson & Johnson: Navigating Challenges and Seizing Growth Opportunities Johnson & Johnson prepares to announce its quarterly earnings amid a backdrop of mixed corporate performances and ongoing chal…
Johnson & Johnson's Earnings Report: A Focus on Long-Term Growth in MedTech and Immunology As Johnson & Johnson prepares to release its fourth-quarter earnings report on Wednesday, analysts and invest…
Johnson & Johnson Partners with Trump Administration to Lower Drug Prices In a significant move to address the pressing issue of high prescription drug costs in the United States, Johnson & Johnson an…